![]() |
|||||||||||||||
![]() |
Cerca | Lliura | Ajuda | Servei de Biblioteques | Sobre el DDD | Català English Español |
Pàgina inicial > Articles > Articles publicats > Nerve growth factor (NGF) pathway biomarkers in Down syndrome prior to and after the onset of clinical Alzheimer's disease : |
Data: | 2020 |
Resum: | The discovery that nerve growth factor (NGF) metabolism is altered in Down syndrome (DS) and Alzheimer's disease (AD) brains offered a framework for the identification of novel biomarkers signalling NGF deregulation in AD pathology. We examined levels of NGF pathway proteins (proNGF, neuroserpin, tissue plasminogen activator [tPA], and metalloproteases [MMP]) in matched cerebrospinal fluid (CSF)/plasma samples from AD-symptomatic (DSAD) and AD-asymptomatic (aDS) individuals with DS, as well as controls (HC). ProNGF and MMP-3 were elevated while tPA was decreased in plasma from individuals with DS. CSF from individuals with DS showed elevated proNGF, neuroserpin, MMP-3, and MMP-9. ProNGF and MMP-9 in CSF differentiated DSAD from aDS (area under the curve = 0. 86, 0. 87). NGF pathway markers associated with CSF amyloid beta and tau and differed by sex. Brain NGF metabolism changes can be monitored in plasma and CSF, supporting relevance in AD pathology. These markers could assist staging, subtyping, or precision medicine for AD in DS. |
Ajuts: | Instituto de Salud Carlos III PI14-01126 Instituto de Salud Carlos III PI17-01019 Instituto de Salud Carlos III PI13-01532 Instituto de Salud Carlos III PI16-01825 Instituto de Salud Carlos III PI18-00335 Instituto de Salud Carlos III PI14-1561 Instituto de Salud Carlos III PI17-01896 Instituto de Salud Carlos III PI18-00435 Instituto de Salud Carlos III PI17-00279 Instituto de Salud Carlos III FI18-00275 |
Nota: | Altres ajuts: This work was also supported by the National Institutes of Health (R21AG056974 and R01AG061566 to JF); Departament de Salut de la Generalitat de Catalunya, Pla Estratègic de Recerca i Innovació en Salut (SLT002/16/00408 to AL); Fundació La Marató de TV3 (20141210 to JF, 044412 to RB). Fundació Catalana Síndrome de Down and Fundació Víctor Grífols i Lucas partially supported this work. This work was also supported by Generalitat de Catalunya (SLT006/17/00119 to JF) and a grant from the Fundació Bancaria La Caixa to RB. |
Drets: | Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, i la comunicació pública de l'obra, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original. No es permet la creació d'obres derivades. |
Llengua: | Anglès |
Document: | Article ; recerca ; Versió publicada |
Matèria: | Alzheimer's disease ; Biomarkers ; Blood ; Cerebrospinal fluid ; Cholinergic ; Down syndrome ; Metalloproteases ; MMP-1 ; MMP-3 ; MMP-9 ; Nerve growth factor ; Neuroserpin ; NGF metabolic pathway ; Plasma ; ProNGF ; Tissue plasminogen activator |
Publicat a: | Alzheimer's & Dementia, Vol. 17 (november 2020) , p. 605-617, ISSN 1552-5279 |
13 p, 1.0 MB |